Vara AI supports breast cancer screening and diagnostic mammography. It returns a BI-RADS-equivalent score, suspiciousness score, density assessment, CAD lesion markers, and a structured AI report - with industry-leading multi-prior analysis across multiple screening rounds. In the PRAIM prospective study (largest prospective study globally, Nature Medicine 2025, n=463,094, 12 sites, 119 radiologists), AI-supported double reading increased cancer detection by +17.6% while maintaining non-inferior recall. Vara is deployed across ~50% of Germany's organized national screening programme - running on all major scanner types with no exclusion criteria - and is one of the only breast imaging AI certified Class IIb for independent reading. In 2026, Vara is expected to receive CE approval for DBT and risk prediction.
